{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:52:45Z","timestamp":1775890365649,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004441","name":"Styrelsen f\u00f6r Internationellt Utvecklingssamarbete","doi-asserted-by":"publisher","award":["51170072"],"award-info":[{"award-number":["51170072"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Studies on pharmacogenetics of praziquantel (PZQ) and its relevance on plasma drug concentrations and schistosomiasis treatment outcomes are lacking. We investigated the effect of pharmacogenetics variations of PZQ on plasma drug levels and schistosomiasis treatment outcomes among infected Tanzanian school-aged children. A total of 340 <jats:italic>Schistosoma mansoni<\/jats:italic> infected children were enrolled and treated with single-dose PZQ. Stool samples analysis was done by thick smear Kato-Katz technique, and treatment efficacy was assessed at 3-weeks post-treatment. Safety was assessed within 4\u00a0h after PZQ intake. Plasma samples were collected at 4\u00a0h post-dose, and PZQ and <jats:italic>trans<\/jats:italic>-4-OH-PZQ concentrations were quantified using UPLCMS\/MS. Genotyping for <jats:italic>CYP3A4*1B<\/jats:italic>, <jats:italic>CYP3A5<\/jats:italic> (*3, *6, *7), <jats:italic>CYP2C19<\/jats:italic> (*2, *3, *17), and <jats:italic>CYP2C9<\/jats:italic> (*2, *3) were done by Real-Time PCR. The median age (range) of the study participants was 12 years (7\u201317). There was a significant association of CYP2C19 genotypes with PZQ concentrations and its metabolic ratio (<jats:italic>trans<\/jats:italic>-4-OH-PZQ\/PZQ). PZQ concentration was significantly higher among <jats:italic>CYP2C19<\/jats:italic> (*2, *3) carriers than <jats:italic>CYP2C19 *1\/*1<\/jats:italic> and <jats:italic>CYP2C19 *17<\/jats:italic> carriers (ultra-rapid metabolizers) (<jats:italic>p<\/jats:italic> = 0.04). The metabolic ratio was significantly higher among <jats:italic>CYP2C19*17<\/jats:italic> carriers than <jats:italic>CYP2C19<\/jats:italic> (*2, *3) carriers (<jats:italic>p<\/jats:italic> = 0.01). No significant effect of <jats:italic>CYP3A4<\/jats:italic>, <jats:italic>CYP3A5<\/jats:italic>, <jats:italic>CYP2C19<\/jats:italic>, and <jats:italic>CYP2C9<\/jats:italic> genotypes on treatment efficacy or adverse events were observed. Baseline infection intensity and <jats:italic>CYP3A5<\/jats:italic> genotype were significant predictors of treatment associated-adverse events. In conclusion, <jats:italic>CYP2C19<\/jats:italic> genotype significantly affects plasma PZQ concentration and its metabolic ratio. For the first time, we report the importance of pharmacogenetic variation for the treatment of schistosomiasis, a neglected tropical disease.<\/jats:p>","DOI":"10.3389\/fphar.2021.712084","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:29:48Z","timestamp":1630708188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania"],"prefix":"10.3389","volume":"12","author":[{"given":"Rajabu Hussein","family":"Mnkugwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omary","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safari","family":"Kinung\u2019hi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Appolinary","family":"Kamuhabwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers11091353","article-title":"CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients","volume":"11","author":"Ahmed","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fphar.2019.00481","article-title":"CYP2J2*7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0005372","DOI":"10.1371\/journal.pntd.0005372","article-title":"Decline in Infection-Related Morbidities Following Drug-Mediated Reductions in the Intensity of Schistosoma Infection: A Systematic Review and Meta-Analysis","volume":"11","author":"Andrade","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/emph\/eot010","article-title":"African Variation at Cytochrome P450 Genes: Evolutionary Aspects and the Implications for the Treatment of Infectious Diseases","volume":"2013","author":"Bains","year":"2013","journal-title":"Evol. Med. Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1128\/mBio.00227-16","article-title":"Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy","volume":"7","author":"Bustinduy","year":"2016","journal-title":"mBio"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12688\/aasopenres.12965.1","article-title":"African Pharmacogenomics Consortium: Consolidating Pharmacogenomics Knowledge, Capacity Development and Translation in Africa","volume":"2","author":"Dandara","year":"2019","journal-title":"AAS Open Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002280100282","article-title":"Genetic Polymorphism of CYP2D6 and CYP2C19 in East- and Southern African Populations Including Psychiatric Patients","volume":"57","author":"Dandara","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/fpc.0b013e3282f50ee9","article-title":"4\u03b2-Hydroxycholesterol Is a New Endogenous CYP3A Marker: Relationship to CYP3A5 Genotype, Quinine 3-hydroxylation and Sex in Koreans, Swedes and Tanzanians","volume":"18","author":"Diczfalusy","year":"2008"},{"key":"B9","first-page":"186","article-title":"Global Distribution of Schistosomiasis: CEGET\/WHO Atlas","volume":"37","author":"Doumenge","year":"1984","journal-title":"World Health Stat. Q."},{"key":"B10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s2221-1691(12)60049-5","article-title":"Efficacy and Side Effects of Praziquantel in the Treatment of Schistosomiasis Mansoni in Schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia","volume":"2","author":"Erko","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"B11","unstructured":"Guideline on Bioanalytical Method Validation EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2"},{"key":"B12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/tpj.2010.16","article-title":"Sex and CYP3A5 Genotype Influence Total CYP3A Activity: High CYP3A Activity and a Unique Distribution of CYP3A5 Variant Alleles in Ethiopians","volume":"11","author":"Gebeyehu","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/pathogens9110920","article-title":"Prevalence, Intensity, and Correlates of Schistosomiasis and Soil-Transmitted Helminth Infections after Five Rounds of Preventive Chemotherapy Among School Children in Southern Ethiopia","volume":"9","author":"Gebreyesus","year":"2020","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2865","DOI":"10.1371\/journal.pntd.0002496","article-title":"The Global burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases","volume":"8","author":"Hotez","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40249-018-0448-x","article-title":"Efficacy of Praziquantel Treatment Regimens in Pre-school and School Aged Children Infected with Schistosomiasis in Sub-saharan Africa: a Systematic Review","volume":"7","author":"Kabuyaya","year":"2018","journal-title":"Infect. Dis. poverty"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13071-017-2293-3","article-title":"In Vitro and In Vivo Activity of R- and S- Praziquantel Enantiomers and the Main Human Metabolite Trans-4-hydroxy-praziquantel against Schistosoma Haematobium","volume":"10","author":"Kova\u010d","year":"2017","journal-title":"Parasit Vectors"},{"key":"B18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of Human Cytochrome P 450 S that Metabolise Anti-parasitic Drugs and Predictions of In Vivo Drug Hepatic Clearance from In Vitro Data","volume":"59","author":"Li","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/tpj.2015.37","article-title":"CYP2B6*6 Genotype and High Efavirenz Plasma Concentration but Not Nevirapine Are Associated with Low Lumefantrine Plasma Exposure and Poor Treatment Response in HIV-Malaria-Coinfected Patients","volume":"16","author":"Maganda","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/1756-3305-5-274","article-title":"Epidemiology and Control of Human Schistosomiasis in Tanzania","volume":"5","author":"Mazigo","year":"2012","journal-title":"Parasit Vectors"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1016\/s2214-109x(19)30271-2","article-title":"Participatory Integrated Control Strategies and Elimination of Schistosomiasis in Sub-saharan Africa","volume":"7","author":"Mazigo","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","article-title":"Taste, a New Incentive to Switch to (R)-praziquantel in Schistosomiasis Treatment","volume":"3","author":"Meyer","year":"2009","journal-title":"Plos Negl. Trop. Dis."},{"key":"B23","article-title":"Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma Mansoni Infection","volume":"14","author":"Minzi","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":"CYP3A5 Genotype Has Significant Effect on Quinine 3-hydroxylation in Tanzanians, Who Have Lower Total CYP3A Activity Than a Swedish Population","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenetics Genomics. Sep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0008619","DOI":"10.1371\/journal.pntd.0008619","article-title":"Efficacy and Safety of Praziquantel and Dihydroartemisinin Piperaquine Combination for Treatment and Control of Intestinal Schistosomiasis: A Randomized, Non-inferiority Clinical Trial","volume":"14","author":"Mnkugwe","year":"","journal-title":"Plos Negl. Trop. Dis."},{"key":"B26","article-title":"Efficacy and Safety of Praziquantel for Treatment of Schistosoma Mansoni Infection Among School Children in Tanzania","volume":"9","author":"Mnkugwe","year":"2019","journal-title":"PathogensBasel, Switzerland)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0228770","DOI":"10.1371\/journal.pone.0228770","article-title":"Prevalence and Correlates of Intestinal Schistosomiasis Infection Among School-Aged Children in North-Western Tanzania","volume":"15","author":"Mnkugwe","year":"","journal-title":"PloS one"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e40180","DOI":"10.1371\/journal.pone.0040180","article-title":"Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-infection in Tanzania","volume":"7","author":"Mugusi","year":"2012","journal-title":"PloS one"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e86919","DOI":"10.1371\/journal.pone.0086919","article-title":"Pharmacogenetic-based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes","volume":"9","author":"Mukonzo","year":"2014","journal-title":"PloS one"},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12936-017-1914-9","article-title":"Effect of Pharmacogenetics on Plasma Lumefantrine Pharmacokinetics and Malaria Treatment Outcome in Pregnant Women","volume":"16","author":"Mutagonda","year":"2017","journal-title":"Malar. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e67946","DOI":"10.1371\/journal.pone.0067946","article-title":"Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: a Parallel-Group Prospective Cohort Study in Two Sub-saharan Africa Populations","volume":"8","author":"Ngaimisi","year":"2013","journal-title":"PloS one"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1093\/jac\/dku286","article-title":"Pharmacokinetic and Pharmacogenomic Modelling of the CYP3A Activity Marker 4 -hydroxycholesterol during Efavirenz Treatment and Efavirenz\/rifampicin Co-treatment","volume":"69","author":"Ngaimisi","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00228-019-02663-8","article-title":"The Effect of Ketoconazole on Praziquantel Pharmacokinetics and the Role of CYP3A4 in the Formation of X-OH-praziquantel and Not 4-OH-praziquantel","volume":"75","author":"Nleya","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bcp.2014.05.001","article-title":"Metabolic Profiling of Praziquantel Enantiomers","volume":"90","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/nejmra032424","article-title":"Drug Metabolism and Variability Among Patients in Drug Response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B36","article-title":"Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Helminthiases","year":"2013"},{"key":"B37","article-title":"Basic Laboratory Methods in Medical Parasitology","year":"1991"},{"key":"B38","article-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity","year":"2011"},{"key":"B39","article-title":"Investing to Overcome the Global Impact of Neglected Tropical Diseases, Third WHO Report on Neglected TropicalDiseases","year":"2015"},{"key":"B40","article-title":"Schistosomiasis and Soiltransmitted Helminthiases: Numbers of People Treated in 2017","year":"2018"},{"key":"B41","article-title":"WHO Anthroplus Software; Software for Assessing Growth and Development of the World's Children and Adolescents","year":"2009"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e94271","DOI":"10.1371\/journal.pone.0094271","article-title":"Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-tuberculosis Drugs: a Prospective Four Arm Observational Study in Ethiopian Patients","volume":"9","author":"Yimer","year":"2014","journal-title":"PloS one"},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High Plasma Efavirenz Level and CYP2B6*6 Are Associated with Efavirenz-Based HAART-Induced Liver Injury in the Treatment of Na\u00efve HIV Patients from Ethiopia: a Prospective Cohort Study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0008649","DOI":"10.1371\/journal.pntd.0008649","article-title":"Drug Metabolism and Pharmacokinetics of Praziquantel: A Review of Variable Drug Exposure during Schistosomiasis Treatment in Human Hosts and Experimental Models","volume":"14","author":"Zdesenko","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1958-7","article-title":"Efficacy and Safety of Praziquantel 40 Mg\/kg in Preschool-Aged and School-Aged Children: a Meta-Analysis. Parasites & Vectors","author":"Zwang","year":"2017"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.712084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:29:52Z","timestamp":1630708192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.712084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":45,"alternative-id":["10.3389\/fphar.2021.712084"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.712084","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"712084"}}